Mylotarg Related Clinical Trials
Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS) [Terminated]
Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS [Completed]
Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk [Active, not recruiting]
Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS) [Completed]
Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia [Completed]
Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia [Recruiting]
Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome [Completed]
DNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AML [Completed]
Prospective Study of Mylotarg and G-CSF in Acute Myeloid Leukemia Treatment [Active, not recruiting]
A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old [Completed]
Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML) [Active, not recruiting]
Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia [Withdrawn]
Acute Promyelocytic Leukemia (APL) Treated With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin [Recruiting]
Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia [Recruiting]
Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS [Completed]
Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes [Completed]
Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia [Completed]
Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML [Completed]
Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4 [Not yet recruiting]
Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS [Recruiting]
Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care [Completed]
SCT Plus Immune Therapy in Average Risk AML/MDS [Recruiting]
Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia [Active, not recruiting]
SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED) [Terminated]
Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML [Terminated]
NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia [Active, not recruiting]
Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene Mutation [Recruiting]
Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations [Not yet recruiting]
A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia [Completed]
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia [Active, not recruiting]
Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM) [Completed]
Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid Leukemia [Not yet recruiting]
Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia [Completed]
Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia [Completed]
S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia [Completed]
Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML) [Completed]
Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant [Completed]
LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) [Completed]
Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia [Completed]
Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia [Recruiting]
Gemtuzumab Ozogamicin, Fludarabine, and Total-body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome [Completed]
Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia [Active, not recruiting]
CMA-676 in Treating Patients With Acute Myeloid Leukemia in First Relapse [Completed]
Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome [Completed]
CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse [Completed]
Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia [Completed]
Biomarkers in DNA Samples From Younger Patients With Newly Diagnosed Acute Myeloid Leukemia Receiving Gemtuzumab Ozogamicin [Active, not recruiting]
Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia [Completed]
Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia [Completed]
Study of Gemtuzumab Ozogamicin Therapy in DNA Samples From Patients With Acute Myeloid Leukemia Treated on COG-AAML0531 [Active, not recruiting]
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy [Available]
Gemtuzumab in Treating Patients With Myelodysplastic Syndrome [Active, not recruiting]
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes [Completed]
Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes [Completed]
S9031-9333-0106-0112-A Study of Biomarkers in Samples From Patients With Acute Myeloid Leukemia Treated With Standard Chemotherapy With or Without Gemtuzumab Ozogamicin [Completed]
Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission [Completed]
Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia [Completed]
Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) [Completed]
Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia [Completed]
Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) [Completed]
ASCT for Relapsed APL After Molecular Remission [Terminated]
|